{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:39:23Z","timestamp":1790419163003,"version":"4.1.0"},"reference-count":97,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Infection"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>The coronavirus disease of 2019 (COVID-19) has caused significant morbidity and mortality among infected individuals across the world. High transmissibility rate of the causative virus \u2013 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) \u2013 has led to immense strain and bottlenecking of the health care system. While noteworthy advances in vaccine development have been made amid the current global pandemic, most therapeutic agents are repurposed from use in other viral infections and are being evaluated for efficacy in COVID-19. Favipiravir, an orally administered drug originally developed in Japan against emerging influenza viral strains, has been shown to have widespread application and safety across multiple ribonucleic acid (RNA) viral infections. With a strong affinity toward the viral RNA-dependent RNA polymerase (RdRp), favipiravir could be a promising therapy against SARS-CoV-2, by targeting downstream viral RNA replication. Initial trials for usage in COVID-19 have suggested that favipiravir administration during initial infection stages, in individuals with mild to moderate infection, has a strong potential to improve clinical outcomes. However, additional well-designed clinical trials are required to closely examine ideal timing of drug administration, dosage, and duration, to assess the role of favipiravir in COVID-19 therapy. This review provides evidence-based insights and throws light on the current clinical trials examining the efficacy of favipiravir in tackling COVID-19, including its mechanism, pharmacodynamics, and pharmacokinetics.<\/jats:p>","DOI":"10.1177\/20499361211063016","type":"journal-article","created":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T07:22:41Z","timestamp":1638602561000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review"],"prefix":"10.1177","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2877-3542","authenticated-orcid":false,"given":"Kritika","family":"Srinivasan","sequence":"first","affiliation":[{"name":"Department of Biomaterials and Pathology, Vilcek Institute, New York University School of Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2516-2079","authenticated-orcid":false,"given":"Mana","family":"Rao","sequence":"additional","affiliation":[{"name":"Essen Medical Associates, 2015 Grand Concourse, Bronx, NY 10453, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,12,4]]},"reference":[{"key":"bibr1-20499361211063016","unstructured":"COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Coronavirus Resource Center, https:\/\/coronavirus.jhu.edu\/map.html"},{"key":"bibr2-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-0695-z"},{"key":"bibr3-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2012-7"},{"key":"bibr4-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1177\/2472555220942123"},{"key":"bibr5-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0400-4"},{"key":"bibr6-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2008-3"},{"key":"bibr7-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2368-8"},{"key":"bibr8-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10280-3"},{"key":"bibr9-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1602591113"},{"key":"bibr10-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1007626107"},{"key":"bibr11-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1126\/science.1259210"},{"key":"bibr12-20499361211063016","doi-asserted-by":"publisher","DOI":"10.3390\/v10020076"},{"key":"bibr13-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-63761-3_11"},{"key":"bibr14-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2020.03.026"},{"key":"bibr15-20499361211063016","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.671788"},{"key":"bibr16-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.12.001"},{"key":"bibr17-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01283-z"},{"key":"bibr18-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1039\/D0LC00373E"},{"key":"bibr19-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2020.09.010"},{"key":"bibr20-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-020-00532-2"},{"key":"bibr21-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2020.07.008"},{"key":"bibr22-20499361211063016","doi-asserted-by":"publisher","DOI":"10.2183\/pjab.93.027"},{"key":"bibr23-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02442-5"},{"key":"bibr24-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2021.06.003"},{"key":"bibr25-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31042-4"},{"key":"bibr26-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.04.026"},{"key":"bibr27-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"bibr28-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.09.015"},{"key":"bibr29-20499361211063016","unstructured":"Toyama Chemical Co., Ltd. Report on the deliberation results \u2013 Avigan (favipiravir) Tablet 200 mg, 2014, https:\/\/www.pmda.go.jp\/files\/000210319.pdf"},{"key":"bibr30-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2014441117"},{"key":"bibr31-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/j.mjafi.2020.08.004"},{"key":"bibr32-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2018.03.003"},{"key":"bibr33-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107512"},{"key":"bibr34-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02346-12"},{"key":"bibr35-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164691"},{"key":"bibr36-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.981-986.2005"},{"key":"bibr37-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068347"},{"key":"bibr38-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01400-17"},{"key":"bibr39-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2017.03.014"},{"key":"bibr40-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01391-15"},{"key":"bibr41-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0909603107"},{"key":"bibr42-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0364-1"},{"key":"bibr43-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005389"},{"key":"bibr44-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1017\/dmp.2014.151"},{"key":"bibr45-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.4.977-981.2002"},{"key":"bibr46-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1177\/095632020301400502"},{"key":"bibr47-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01051-06"},{"key":"bibr48-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.02.198"},{"key":"bibr49-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1811345115"},{"key":"bibr50-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00933-09"},{"key":"bibr51-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz656"},{"key":"bibr52-20499361211063016","unstructured":"Avigan Tablets 200 mg, https:\/\/www.cdc.gov.tw\/File\/Get\/ht8jUiB_MI-aKnlwstwzvw"},{"key":"bibr53-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103125"},{"key":"bibr54-20499361211063016","unstructured":"MDVI. Dose-finding study of favipiravir in the treatment of uncomplicated influenza, 2014, https:\/\/clinicaltrials.gov\/show\/NCT01068912"},{"key":"bibr55-20499361211063016","unstructured":"Phase 3 efficacy and safety study of favipiravir for treatment of uncomplicated influenza in adults \u2013 T705US316, https:\/\/clinicaltrials.gov\/show\/NCT02026349"},{"key":"bibr56-20499361211063016","unstructured":"Phase 3 efficacy and safety study of favipiravir for treatment of uncomplicated influenza in adults, https:\/\/clinicaltrials.gov\/show\/NCT02008344"},{"key":"bibr57-20499361211063016","volume":"13","author":"Sissoko D","year":"2016","journal-title":"PLoS Med"},{"key":"bibr58-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz078"},{"key":"bibr59-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002535"},{"key":"bibr60-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00356-07"},{"key":"bibr61-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01074-08"},{"key":"bibr62-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2008.07.009"},{"key":"bibr63-20499361211063016","unstructured":"World Health Organization. Nipah virus infection, https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/nipah-virus"},{"key":"bibr64-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-25780-3"},{"key":"bibr65-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00709-16"},{"key":"bibr66-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202000047"},{"key":"bibr67-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.15.098731"},{"key":"bibr68-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30114-5"},{"key":"bibr69-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa851"},{"key":"bibr70-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.10.069"},{"key":"bibr71-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0282-0"},{"key":"bibr72-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00016-0"},{"key":"bibr73-20499361211063016","doi-asserted-by":"publisher","DOI":"10.5582\/ddt.2020.01012"},{"key":"bibr74-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/S2055-6640(20)30016-9"},{"key":"bibr75-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.17.20037432"},{"key":"bibr76-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06164-x"},{"key":"bibr77-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.14.21251693"},{"key":"bibr78-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105631"},{"key":"bibr79-20499361211063016","doi-asserted-by":"publisher","DOI":"10.3390\/idr13020029"},{"key":"bibr80-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01897-20"},{"key":"bibr81-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.11.142"},{"key":"bibr82-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1176"},{"key":"bibr83-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/j.eng.2020.03.007"},{"key":"bibr84-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110825"},{"key":"bibr85-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.11.008"},{"key":"bibr86-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107522"},{"key":"bibr87-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85227-0"},{"key":"bibr88-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-021-04956-9"},{"key":"bibr89-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04825-x"},{"key":"bibr90-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04747-8"},{"key":"bibr91-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04891-1"},{"key":"bibr92-20499361211063016","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1186\/s13063-020-04619-1","volume":"21","author":"Duvignaud A","year":"2020","journal-title":"Trials"},{"key":"bibr93-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04766-5"},{"key":"bibr94-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05139-2"},{"key":"bibr95-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-046799"},{"key":"bibr96-20499361211063016","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00461-X"},{"key":"bibr97-20499361211063016","unstructured":"Yu L-M, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv 2021, http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2021.04.10.21254672 (accessed 25 July 2021)."}],"container-title":["Therapeutic Advances in Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20499361211063016","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20499361211063016","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20499361211063016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:58:28Z","timestamp":1777593508000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20499361211063016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":97,"alternative-id":["10.1177\/20499361211063016"],"URL":"https:\/\/doi.org\/10.1177\/20499361211063016","relation":{},"ISSN":["2049-9361","2049-937X"],"issn-type":[{"value":"2049-9361","type":"print"},{"value":"2049-937X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"20499361211063016"}}